Canakinumab first-line steroid-free treatment in newly diagnosed systemic juvenile idiopathic arthritis

Phase 4, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD), sponsored by Asklepios Klinik Sankt Augustin. Primary endpoint: High response rates with steroid-free inactive disease at month 3 and medication-free remission at month 12. Started Jul 2019; status: completed.